ArticleAntimicrobial agents and chemotherapy1996
Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
Article in Antimicrobial agents and chemotherapy, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.Antimicrobial agents and chemotherapy · 2001Trial
- EfpA is required for regrowth ofAntimicrobial agents and chemotherapy · 2024Article
- Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.Antimicrobial agents and chemotherapy · 2004Article
- Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.Antimicrobial agents and chemotherapy · 2003Article
- Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.Antimicrobial agents and chemotherapy · 2000Article
- Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.Antimicrobial agents and chemotherapy · 2000Article
- High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.Antimicrobial agents and chemotherapy · 1999Article
- Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.Antimicrobial agents and chemotherapy · 1999Article
- Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.Antimicrobial agents and chemotherapy · 1996Article
- Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.Antimicrobial agents and chemotherapy · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The activity of KRM-1648, alone and in combination with isoniazid, was compared with those of isoniazid, rifampin, and the combination of rifampin plus isoniazid in a murine model of tuberculosis. Four-week-old female CD-1 mice were infected intravenously with approximately 10(7) viable Mycobacterium tuberculosis ATCC 35801 organisms. Treatment was started 1 week postinfection and was given by gavage 5 days per week. The duration of the treatment phase was 12 weeks, with groups of mice sacrificed at 2, 4, 6, 8, and 12 weeks. For the observation phase, additional groups of treated mice were sacrificed at 4, 8, 16, and 24 weeks after the cessation of treatment. Viable cell counts were determined from homogenates of the spleens and the right lungs. KRM-1648 was the most active single agent evaluated and resulted in no detectable CFUs in the spleens and lungs by the end of 6 weeks of treatment. Neither rifampin nor isoniazid reduced cell counts to undetectable levels, even after 12 weeks of treatment. The combination of KRM-1648 plus isoniazid was much more active than rifampin plus isoniazid. KRM-1648 plus isoniazid resulted in the apparent sterilization of organs at 6 months following the cessation of treatment. The promising activity of KRM-1648 may allow for ultrashort-course therapy of tuberculosis, i.e., treatment regimens of 4 months or less.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.